ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reported Q2 2017 earnings this Afternoon, coming in at ($0.55) per share, beating Wall Street’s estimates of ($0.72) per Share. Revenue for the quarter came in at $30.50 million beating analyst estimates of $20.02 million
Analyst Coverage For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
These are 3 Hold Ratings, 10 Buy Ratings .
The current consensus rating for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Buy (Score: 2.77) with a consensus target price of $43.15 , a potential (46.09% upside)Recent Insider Trading for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
- On 7/20/2017 Glenn Baity, EVP, sold 38,097 with an average share price of $30.00 per share and the total transaction amounting to $1,142,910.00.
- On 6/22/2017 Glenn Baity, EVP, sold 1,903 with an average share price of $30.00 per share and the total transaction amounting to $57,090.00.
- On 2/16/2017 Terrence O. Moore, EVP, sold 157,540 with an average share price of $39.77 per share and the total transaction amounting to $6,265,365.80.
- On 12/27/2016 Glenn Baity, EVP, sold 9,800 with an average share price of $30.46 per share and the total transaction amounting to $298,508.00.
- On 12/20/2016 Glenn Baity, EVP, sold 10,000 with an average share price of $30.00 per share and the total transaction amounting to $300,000.00.
- On 8/16/2016 Edmund Harrigan, Director, bought 1,000 with an average share price of $32.97 per share and the total transaction amounting to $32,970.00.
Recent Trading for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 29.54 down -1.03 -3.37% with 1,758,716 shares trading hands.